ClinicalTrials.gg
CompletedNCT04188015Updated Aug 20, 2020

Study of ANX007 in Participants With Primary Open-angle Glaucoma

A Phase 1 interventional study of 2.5mg ANX007 and 5.0mg ANX007 in Open Angle Glaucoma, sponsored by Annexon, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-20.

Sponsored by Annexon, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2019, 7 years 5 months ago, and no results have been posted to the registry.
  • Registered 4 months after the study started (first participant enrolled Jul 2018, registered Dec 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.

Enrollment
251st of 279
17 · median 84
Started
2018
with 15 others
Phase 1
19 of 348
2 open now
Registered
204th of 348
by date

Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 251st largest by enrollment of the 279 interventional ones that give a count, is one of 16 that started in 2018, is one of 19 in phase 1, and was the 204th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 348 studies in Glaucoma, Open-Angle with a site in United States, or all of them as a file.
02

Study summary

This is a double-masked, randomized, sham-controlled study evaluating two dose levels of ANX007 vs sham, administered as repeat Intravitreal (IVT) injections in patients with Primary Open-angle Glaucoma.

Read the detailed description

This is a phase 1b, double-masked, sham-controlled study evaluating 2 dose levels of ANX007 administered as 2 IVT injections separated by 4 weeks. Approximately 15-29 subjects will be enrolled. An interim analysis of the initial set of 15 participants may be conducted. Based on this analysis, an additional 10-14 participants may be enrolled at a 1:1 ratio to receive one of the two dose levels.

The primary objective is to evaluate the safety and tolerability of repeat IVT injections of ANX007 in participants with primary open-angle glaucoma. Secondary objectives are to evaluate the anterior chamber fluid pharmacokinetics (PK) of ANX007, PD effect of ANX007 on anterior chamber fluid C1q activity, and immunogenicity. An exploratory objective will evaluate ocular PD effect of ANX007.

03

Conditions studied

  • Open Angle Glaucoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female age 18 years, and above.
  2. Diagnosis of primary open-angle glaucoma.
  3. Ability to perform a reliable visual field test in the study eye with a cutoff of 33% for fixation losses and 33% for false-positive response rates.
  4. Intraocular pressure (IOP) \<21 mm Hg at screening and Day 1.
  5. The IOP treatment regimen in the study eye should be stable for at least 4 weeks prior to injection, with no change in the IOP treatment regimen anticipated throughout study participation.
  6. Ability to comply with the requirements of the study and complete the full sequence of protocol specified injections, procedures, and evaluations.

Exclusion criteria

Exclusion Criteria:

  1. Extensive glaucomatous visual-field damage with a mean deviation worse than -18 dB on Humphrey visual field testing.
  2. Any current or prior ocular pathology, other than glaucoma, which could interfere with the conduct of the study including, but not limited to, retinal or optic nerve disease and media opacity in the study eye.
  3. History of intraocular inflammatory or infectious eye disease in the study eye.
  4. Ocular trauma in the study eye within the preceding 6 months.
  5. A history of uncomplicated cataract surgery less than 3 months prior to injection, or trabeculectomy, iridotomy, or other ocular procedures in the study eye that could affect drug distribution and excretion.
  6. Any abnormality preventing reliable tonometry in the study eye.
  7. Concurrent use of medications administered by any ocular or systemic route. Nasal, inhaled, and dermatologic (if not administered around the eyes) glucocorticoids are permitted.
  8. Receiving monoamine oxidase inhibitor therapy or patient-reported to any component of apraclonidine, brimonidine, clonidine, phenylephrine, povidone iodine, proparacaine, or ANX007.
  9. Active or history of within the past 5 years with the exception of curatively treated, basal cell carcinoma.
  10. Previous treatment with another humanized monoclonal antibody, Fab or Fab'2.
  11. History of any or neurologic disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    2.5mg ANX007

    1 in every 3 subjects will be randomized to 2.5mg dose of ANX007.

    Biological: 2.5mg ANX007

  • Experimental
    5.0mg ANX007

    1 in every 3 subjects will be randomized to 5.0mg dose of ANX007.

    Biological: 5.0mg ANX007

  • Sham comparator
    Sham Procedure

    1 in every 3 subjects will have a sham procedure performed instead of receiving ANX007.

    Other: Sham Procedure

Interventions

  • Biological2.5mg ANX007

    A single dose of 2.5mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.

  • Biological5.0mg ANX007

    A single dose of 5.0mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.

  • OtherSham Procedure

    The sham injection is preformed by applying pressure to the eye at the location of a typical IVT injection using the blunt end of a syringe without a needle.

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of ANX007 in participants with primary open-angle glaucoma as measured by occurrence of treatment-emergent adverse events.

    Time frame: Day 85

Secondary outcomes

  1. Evaluate PK parameters of ANX007 in serum after repeat injections

    Maximum Serum Concentration (Cmax) of ANX007

    Time frame: Day 29

  2. Evaluate PK parameters of ANX007 in serum after repeat injections

    Area Under the Curve (AUC) of ANX007

    Time frame: Day 29

  3. Evaluate PK parameters of ANX007 in aqueous humor after repeat intravitreal injections

    Maximum aqueous humor Concentration (Cmax) of ANX007

    Time frame: Day 29

  4. Evaluate PK parameters of ANX007 in aqueous humor after repeat intravitreal injections

    Aqueous humor Area Under the Curve (AUC) of ANX007

    Time frame: Day 29

  5. Evaluate PD parameters of ANX007 in aqueous humor after repeat intravitreal injections

    Maximum C1q concentration (Cmax) in aqueous humor

    Time frame: Day 29

  6. Evaluate PD parameters of ANX007 in aqueous humor after repeat intravitreal injections

    C1q area under the curve (AUC) in aqueous humor

    Time frame: Day 29

  7. Evaluate PD parameters of ANX007 in serum after repeat intravitreal injections

    Maximum C1q concentration (Cmax) in serum

    Time frame: Day 29

  8. Evaluate PD parameters of ANX007 in serum after repeat intravitreal injections

    C1q concentration area under the curve (AUC) in serum

    Time frame: Day 29

  9. Immunogenicity of ANX007 as measured by serum anti-drug antibodies (ADA) after repeat intravitreal injections of ANX007

    Incidence of positive antibody titre against ANX007 in serum

    Time frame: Day 84

07

Study locations

2 sites
  • Eye Research Foundation
    Newport Beach, California 94303, United States
  • Stanford Health Care
    Stanford, California 94305, United States
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Jun 2019, 10 months.

Of 17 phase 1 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 23. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2018
First posted
Dec 5, 2019
StartActual
Jul 25, 2018
Primary completionActual
Jun 3, 2019
CompletionActual
Jun 3, 2019
Last update
Aug 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04188015
Lead sponsor
Annexon, Inc.
Responsible party
Sponsor
First posted
Dec 5, 2019
Start date
Jul 25, 2018
Primary completion
Jun 3, 2019
Completion
Jun 3, 2019
Last update
Aug 20, 2020

Study contacts

Eric Humphriss
study director · Annexon Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonaprument

Start the discussion